These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 34822948)

  • 1. Naturally occurring mutations in G protein-coupled receptors associated with obesity and type 2 diabetes mellitus.
    Liu T; Ji RL; Tao YX
    Pharmacol Ther; 2022 Jun; 234():108044. PubMed ID: 34822948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. G protein-coupled receptors as therapeutic targets for obesity and type 2 diabetes.
    Bjenning C; Al-Shamma H; Thomsen W; Leonard J; Behan D
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1051-62. PubMed ID: 15535426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. G-protein-coupled receptors (GPCRs) in the treatment of diabetes: Current view and future perspectives.
    Sebastiani G; Ceccarelli E; Castagna MG; Dotta F
    Best Pract Res Clin Endocrinol Metab; 2018 Apr; 32(2):201-213. PubMed ID: 29678286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G Protein-Coupled Receptors Targeting Insulin Resistance, Obesity, and Type 2 Diabetes Mellitus.
    Riddy DM; Delerive P; Summers RJ; Sexton PM; Langmead CJ
    Pharmacol Rev; 2018 Jan; 70(1):39-67. PubMed ID: 29233848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting appetite and satiety in diabetes and obesity, via G protein-coupled receptors.
    Piper NBC; Whitfield EA; Stewart GD; Xu X; Furness SGB
    Biochem Pharmacol; 2022 Aug; 202():115115. PubMed ID: 35671790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor Agonists.
    Ji Q
    Clin Ther; 2017 Jun; 39(6):1244-1264. PubMed ID: 28526416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes.
    Barella LF; Jain S; Kimura T; Pydi SP
    FEBS J; 2021 Apr; 288(8):2622-2644. PubMed ID: 33682344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.
    Abbas G; Haq QMI; Hamaed A; Al-Sibani M; Hussain H
    Curr Pharm Des; 2020; 26(4):501-508. PubMed ID: 32003684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RISING STARS: Targeting G protein-coupled receptors to regulate energy homeostasis.
    Jamaluddin A; Gorvin CM
    J Mol Endocrinol; 2023 May; 70(4):. PubMed ID: 36943057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives.
    Quiñones M; Fernø J; Diéguez C; Nogueiras R; Al-Massadi O
    Expert Opin Drug Discov; 2019 May; 14(5):421-431. PubMed ID: 30821530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory G proteins and their receptors: emerging therapeutic targets for obesity and diabetes.
    Kimple ME; Neuman JC; Linnemann AK; Casey PJ
    Exp Mol Med; 2014 Jun; 46(6):e102. PubMed ID: 24946790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in obestatin gene and GPR39 receptor expression in peripheral tissues of rat models of obesity, type 1 and type 2 diabetes.
    Kolodziejski PA; Pruszynska-Oszmalek E; Sassek M; Kaczmarek P; Szczepankiewicz D; Billert M; Mackowiak P; Strowski MZ; Nowak KW
    J Diabetes; 2017 Apr; 9(4):353-361. PubMed ID: 27106635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivating mutations of G protein-coupled receptors and diseases: structure-function insights and therapeutic implications.
    Tao YX
    Pharmacol Ther; 2006 Sep; 111(3):949-73. PubMed ID: 16616374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual-agonist incretin peptides from fish with potential for obesity-related Type 2 diabetes therapy - A review.
    Conlon JM; O'Harte FPM; Flatt PR
    Peptides; 2022 Jan; 147():170706. PubMed ID: 34861327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. G protein-coupled receptors in energy homeostasis.
    Wang J; Xiao R
    Sci China Life Sci; 2014 Jul; 57(7):672-80. PubMed ID: 24969703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GPR120 agonists for the treatment of diabetes: a patent review (2014 present).
    Zhang X; Macielag MJ
    Expert Opin Ther Pat; 2020 Oct; 30(10):729-742. PubMed ID: 32799609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.
    Meister J; Wang L; Pydi SP; Wess J
    J Neurochem; 2021 Aug; 158(3):603-620. PubMed ID: 33540469
    [TBL] [Abstract][Full Text] [Related]  

  • 18. G protein-coupled receptors: abnormalities in signal transmission, disease states and pharmacotherapy.
    Zalewska M; Siara M; Sajewicz W
    Acta Pol Pharm; 2014; 71(2):229-43. PubMed ID: 25272642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
    Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
    Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G protein-coupled receptors as targets for anti-diabetic therapeutics.
    Oh DY; Olefsky JM
    Nat Rev Drug Discov; 2016 Mar; 15(3):161-72. PubMed ID: 26822831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.